Pharmaceuticals by P/E ratio
Share price divided by the last twelve months' earnings per share: how many years of today's profit the price pays for. A company making a loss has none.
Edgewise Therapeutics has the lowest figure of the 33 pharmaceuticals ranked by P/E ratio, at 4.9, followed by Alnylam Pharmaceuticals (7.7) and Novo Nordisk (10.0). Figures as of 18 Nov 2026, 15:42 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 33
- Lowest
- Edgewise Therapeutics4.9
- Median
- 40.2
- Combined market value
- ZAR 87.59T
- Countries
- 10
- Not ranked
- 28no P/E ratio on file
Market values as of .
All countries▾
All sectors▾
Pharmaceuticals▾
| # | Company | P/E ↑ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Edgewise TherapeuticsEWTX · Health Care | 4.9 | ZAR 76.8B | ZAR 701.89 | 3.13% down | 88% up | ||
| 2 | Alnylam PharmaceuticalsALNY · Health Care | 7.7 | ZAR 353.3B | ZAR 2,637.54 | 2.21% down | 66% down | ||
| 3 | Novo NordiskNVO · Health Care | 10.0 | ZAR 3T | ZAR 680.78 | 2.95% down | 17% down | ||
| 4 | GrifolsGRFS · Health Care | 10.3 | ZAR 99.8B | ZAR 146.67 | 1.39% down | 1% up | ||
| 5 | Bristol-Myers SquibbBMY · Health Care | 13.3 | ZAR 2.11T | ZAR 1,031.16 | 2.48% down | 34% up | ||
| 6 | ZoetisZTS · Health Care | 14.2 | ZAR 585.9B | ZAR 1,442.04 | 0.23% up | 29% down | ||
| 7 | GSKGSK · Health Care | 17.0 | ZAR 1.69T | ZAR 841.75 | 0.81% down | 6% up | ||
| 8 | Ascendis PharmaASND · Health Care | 17.8 | ZAR 305.3B | ZAR 4,653.94 | 0.43% down | 28% up | ||
| 9 | Regeneron PharmaceuticalsREGN · Health Care | 21.1 | ZAR 1.7T | ZAR 16,458.11 | 0.30% down | 36% up | ||
| 10 | United TherapeuticsUTHR · Health Care | 21.5 | ZAR 418.4B | ZAR 9,824.32 | 2.41% down | 23% up | ||
| 11 | SanofiSNY · Health Care | 23.5 | ZAR 1.96T | ZAR 815.04 | 0.50% down | 4% down | ||
| 12 | AstraZenecaAZN · Health Care | 25.3 | ZAR 4.78T | ZAR 3,082.29 | 1.88% down | 2% up | ||
| 13 | Protagonist TherapeuticsPTGX · Health Care | 26.3 | ZAR 140B | ZAR 2,145.57 | 0.14% down | 46% up | ||
| 14 | NovartisNVS · Health Care | 29.8 | ZAR 5.09T | ZAR 2,695.19 | 1.73% down | 25% up | ||
| 15 | Vertex PharmaceuticalsVRTX · Health Care | 34.3 | ZAR 2.33T | ZAR 9,187.92 | 0.21% down | 27% up | ||
| 16 | Abbott LaboratoriesABT · Health Care | 38.9 | ZAR 3.11T | ZAR 1,795.53 | 0.51% down | 17% down | ||
| 17 | PfizerPFE · Health Care | 40.2 | ZAR 2.76T | ZAR 485.08 | 1.14% down | 14% up | ||
| 18 | Dr. Reddy's LaboratoriesRDY · Health Care | 41.5 | ZAR 214.7B | ZAR 257.58 | 1.05% up | 5% up | ||
| 19 | Johnson & JohnsonJNJ · Health Care | 41.7 | ZAR 11.41T | ZAR 4,739.77 | 1.32% down | 38% up | ||
| 20 | GenmabGMAB · Health Care | 43.8 | ZAR 544.7B | ZAR 883.46 | 1.35% down | 70% up | ||
| 21 | Royalty PharmaRPRX · Health Care | 44.7 | ZAR 677.2B | ZAR 1,177.83 | 0.50% down | 78% up | ||
| 22 | Eli LillyLLY · Health Care | 45.2 | ZAR 21.39T | ZAR 24,011.99 | 1.58% down | 35% up | ||
| 23 | AbbVieABBV · Health Care | 49.4 | ZAR 8.76T | ZAR 4,953.48 | 1.85% down | 26% up | ||
| 24 | Corcept TherapeuticsCORT · Health Care | 50.7 | ZAR 127.1B | ZAR 1,161.67 | 3.81% down | 8% down | ||
| 25 | BeOne MedicinesONC · Health Care | 51.7 | ZAR 794.4B | ZAR 6,954.36 | 2.36% down | 17% up | ||
| 26 | Amneal PharmaceuticalsAMRX · Health Care | 53.6 | ZAR 128.8B | ZAR 369.69 | 1.56% up | 83% up | ||
| 27 | Jazz PharmaceuticalsJAZZ · Health Care | 71.8 | ZAR 268.5B | ZAR 4,182.22 | 0.81% up | 37% up | ||
| 28 | Kiniksa Pharmaceuticals InternationalKNSA · Health Care | 72.3 | ZAR 129.3B | ZAR 1,645.93 | 0.41% up | 126% up | ||
| 29 | TG TherapeuticsTGTX · Health Care | 94.4 | ZAR 164.8B | ZAR 1,090.28 | 0.88% up | 107% up | ||
| 30 | Teva Pharmaceutical IndustriesTEVA · Health Care | 98.3 | ZAR 849.9B | ZAR 728.35 | 0.84% down | 74% up | ||
| 31 | Ligand PharmaceuticalsLGND · Health Care | 118 | ZAR 101.6B | ZAR 5,079.47 | 0.31% up | 43% up | ||
| 32 | Merck & CoMRK · Health Care | 141 | ZAR 5.94T | ZAR 2,407.89 | 2.55% down | 51% up | ||
| 33 | Takeda PharmaceuticalTAK · Health Care | 305 | ZAR 1.18T | ZAR 368.40 | 1.22% down | 54% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Sums are converted from US dollars at today's exchange rate (1 USD = 17.2349 ZAR). 28 companies have no P/E ratio on file and are not ranked here.
Questions and answers
Which pharmaceuticals have the lowest P/E ratio?
Edgewise Therapeutics (4.9), Alnylam Pharmaceuticals (7.7) and Novo Nordisk (10.0) have the lowest P/E ratio of the 33 pharmaceuticals ranked here as of 18 Nov 2026, 15:42 UTC.
How many pharmaceuticals are in this ranking?
33 are ranked by P/E ratio. 28 more have no P/E ratio on file and are left out rather than ranked at zero.
What are these pharmaceuticals worth together?
The 33 pharmaceuticals ranked by P/E ratio have a combined market value of ZAR 87.59T as of 18 Nov 2026, 15:42 UTC.
What does ranking by P/E ratio measure?
Share price divided by the last twelve months' earnings per share: how many years of today's profit the price pays for. A company making a loss has none.
Learn how this ranking works
All markets guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- PEG ratio: P/E adjusted for growth, and its limits
The PEG ratio is a stock's P/E divided by its expected yearly earnings growth in percent. A P/E of 20 with 10% expected growth gives a PEG of 2; with 20% growth, a PEG of 1. A PEG near 1 is the traditional rough mark of a fair price, but the growth figure is a forecast and often wrong.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Pharmaceuticals by P/E ratio”, data as of 18 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?by=pe-ratio
Underlying data: Yahoo Finance; SEC EDGAR.